St. Anna Kinderkrebsforschung
14
2
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
7.1%
1 terminated/withdrawn out of 14 trials
85.7%
-0.8% vs industry average
29%
4 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
COVID-19: Infectious Potential of SARS-CoV-2 Intestinal Shedding in Pediatric Patients (INPOSIS)
Role: lead
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Role: lead
Pre-existing Kinase Domain Mutations in Ph-positive Leukemias
Role: lead
Allogeneic Stem Cell Transplantation for Children With CML
Role: lead
Optimized Diagnostics for Improved Therapy Stratification in Invasive Fungal Infections
Role: lead
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
Role: lead
ch14.18/CHO Bridging Study
Role: lead
Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)
Role: lead
Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation
Role: lead
Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004
Role: collaborator
Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours
Role: collaborator
Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia
Role: lead
ALL-SCT BFM International- HSCT in Children and Adolescents With ALL
Role: lead
Interleukin-2 in Treating Children With Stage IV Neuroblastoma Who Have Received Induction Therapy and Peripheral Stem Cell Transplantation
Role: lead
All 14 trials loaded